ATIM-01. A PHASE II OPEN-LABEL SINGLE ARM MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RE-IRRADIATION IN ADULT SUBJECTS WITH TRANSFORMED IDH MUTANT GLIOBLASTOMA

摘要

INTRODUCTIONIsocitrate dehydrogenase (IDH) mutant gliomas are relatively indolent, however nearly all IDH mutant gliomas eventually transform to secondary glioblastoma (GBM) for which no effective salvage therapy exists. Transformation to secondary GBM is associated with a high rate of chemotherapy-induced hypermutation phenotype in IDH mutant glioma. Therefore, we aimed to test the safety and efficacy of avelumab, an anti-PD-L1 antibody, and hypofractionated re-irradiation in transformed IDH mutant GBM patients.